LB-3 | Clinical Outcomes of the XIENCE Skypoint 48mm Drug-Eluting Stent in Long Coronary Artery Lesions: Primary Endpoint Data from the SPIRIT 48 Trial

PCI for long, diffuse lesions may often require multiple stents. Concerns remain with overlapping stents, including geographic miss involving two increase in procedural time, contrast use, radiation dose and cost. The availability use of longer stents can circumvent the need facilitate interventional management patients coronary artery lesions. prospective, single-arm, open-label SPIRIT 48 trial evaluated safety efficacy Abbott’s next-generation drug-eluting stent mm everolimus-eluting system (EECSS) (called "ABT NG DES 48") or XIENCE Skypoint IDE, subjects disease long de novo native enrolled 107 at 25 sites 3 countries. Patients were required to have one target lesion that would be treated ABT 48. primary endpoint this study was failure (TLF; composite cardiac death, target-vessel MI clinically indicated TLR) 1-year follow-up compared a pre-specified performance goal (PG) 20% adjudicated by an independent Clinical Events Committee (CEC). This recently completed its follow-up. achieved device success rate 97.2%, which reflects deliverability In addition, 5.8% (6/104 subjects) death/all 1yr attests device. Importantly, met endpoint, TLF 5.7%, upper bound 95% CI 9.5%, significantly lower than PG. definite/probable thrombosis 1 year occurred only subject (1.0%). obtained robust data collected through peak COVID-19 pandemic. from presents strong evidence supporting deliverability, effectiveness, 48mm treating